Mackenzie L Cottrell

Dr. Mackenzie L Cottrell


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2017 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MCMackenzie L Cottrell
Mackenzie L Cottrell
KGKaty L. Garrett
Katy L. Garrett
HPHeather M. A. Prince
Heather M. A. Prince
CSCraig Sykes
Craig Sykes
ASAmanda Schauer
Amanda Schauer
AKAngela D. M. Kashuba
Angela D. M. Kashuba
Objectives: Tenofovir alafenamide, a prodrug of tenofovir, produces higher PBMC concentrations of tenofovir diphosphate (tenofovir-dp) than tenofovir disoproxil fumarate. To understand tenofovir alafenamide’s mucosal tissue distribution and its implications for pre-exposure prophylaxis, we characterized tenofovir-dp in female genital tract (FGT) and lower gastrointestinal (GI) tissues. Methods: Healthy seronegative women were given 5, 10 or 25 mg of tenofovir alafenamide (n = 8/group). Each participant provided plasma, PBMC and cervical, vaginal and rectal tissue samples over 14 days. Plasma, cell lysate and tissue homogenate concentrations were analysed by LC-MS/MS. Dose proportionality was declared in plasma and PBMCs if the natural log AUC versus natural log dose regression line 90% CI was within 0.57–1.43. In vitro tenofovir-dp formation was assessed in PBMCs and ectocervical (Ect1/E6E7) and vaginal (VK2/E6E7) cells incubated in 0.5 and 10 μM tenofovir alafenamide or tenofovir. clinicaltrials.gov: NCT02357602. Results: Following single doses of 5, 10 and 25 mg, median (IQR) tenofovir plasma AUC0–14 days was 52.8 (49.5–59.6), 78.1 (68.2–86.9) and 169.7 (131.2–211.4) ng·h/mL and tenofovir-dp PBMC AUC0–14 days was 2268 (1519–4090), 4584 (3113–5734) and 9306 (6891–10785) fmol·h/106 cells, respectively. Tenofovir was quantifiable in 52% and 92% of FGT and GI tissues, whereas tenofovir-dp was quantifiable in only 5% and 19% of FGT and GI tissues, respectively. Plasma tenofovir and PBMC tenofovir-dp were dose proportional (90% CI = 0.87–1.15 and 0.62–1.02, respectively). In vitro tenofovir-dp was 1.7–17-fold higher in epithelial cells than PBMCs. Conclusions: After tenofovir alafenamide dosing in vivo, tenofovir-dp was unquantifiable in most tissues (91%) although cervical and vaginal epithelial cells efficiently formed tenofovir-dp from tenofovir alafenamide in vitro. These findings warrant further investigation of tenofovir alafenamide’s pharmacology.

10 September 2018 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
JMJohn T Mitchell
John T Mitchell
SLSara LeGrand
Sara LeGrand
LHLisa Hightow-Weidman
Lisa Hightow-Weidman
MMMehri S McKellar
Mehri S McKellar
AKAngela Dm Kashuba
Angela Dm Kashuba
FMF Joseph McClernon
F Joseph McClernon
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Pre-exposure prophylaxis (PrEP) provides a strong preventative benefit to individuals at-risk for HIV. While PrEP adherence is highly correlated with its efficacy, adherence rates are variable both across and within persons. Objective: The objective of this study was to develop and pilot test a smartphone-based intervention, called mSMART, that targets PrEP adherence. mSMART provides contingency management (CM) in the form of monetary incentives for daily PrEP adherence based on a real-time adherence assessment using a camera-based medication event-monitoring tool, as well as medication reminders, PrEP education, individualized behavioral strategies to address PrEP adherence barriers, and medication adherence feedback. Methods: This was a four-week open-label, phase I trial in a community sample of young men who have sex with men already on PrEP (n = 10). Results: While adherence composite scores corresponding to PrEP biomarkers indicated 90% (n = 9) of the sample already had an acceptable baseline adherence in the protective range, by the end of the four-week period scores improved for 30% (n = 3) of the sample—adherence did not worsen for any participants. Participants reported mean PrEP adherence rates of 91% via daily entries in mSMART. At the end of the four-week period, participants indicated acceptable ratings of satisfaction, usability, and willingness to recommend mSMART to others. There were no technical difficulties associated with smartphone compatibility, user misunderstandings about mSMART features that interfered with daily use, or study attrition. Conclusions: This research is the first to apply CM to PrEP adherence. Findings indicated that mSMART is feasible and acceptable. Such an adherence intervention administered via a user-friendly smartphone application can allow for widespread dissemination. Future efficacy trials are needed. Clinical Trial: ClinicalTrials.gov NCT02895893

9 April 2019 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MCMackenzie L Cottrell
Mackenzie L Cottrell
HPHeather M A Prince
Heather M A Prince
ASAmanda P Schauer
Amanda P Schauer
CSCraig Sykes
Craig Sykes
KMKaitlyn Maffuid
Kaitlyn Maffuid
AKAngela D M Kashuba
Angela D M Kashuba
Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP’s active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (ρ = –0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy. Clinical Trials Registration. NCT02983110.

25 May 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
AFAlison F. Feder
Alison F. Feder
CKChristopher Kline
Christopher Kline
PPPatricia Polacino
Patricia Polacino
MCMackenzie L Cottrell
Mackenzie L Cottrell
AKAngela D. M. Kashuba
Angela D. M. Kashuba
ZAZandrea Ambrose
Zandrea Ambrose
The process by which drug-resistant HIV-1 arises and spreads spatially within an infected individual is poorly understood. Studies have found variable results relating how HIV-1 in the blood differs from virus sampled in tissues, offering conflicting findings about whether HIV-1 throughout the body is homogeneously distributed. However, most of these studies sample only two compartments and few have data from multiple time points. To directly measure how drug resistance spreads within a host and to assess how spatial structure impacts its emergence, we examined serial sequences from four macaques infected with RT-SHIVmne027, a simian immunodeficiency virus encoding HIV-1 reverse transcriptase (RT), and treated with RT inhibitors. Both viral DNA and RNA (vDNA and vRNA) were isolated from the blood (including plasma and peripheral blood mononuclear cells), lymph nodes, gut, and vagina at a median of four time points and RT was characterized via single-genome sequencing. The resulting sequences reveal a dynamic system in which vRNA rapidly acquires drug resistance concomitantly across compartments through multiple independent mutations. Fast migration results in the same viral genotypes present across compartments, but not so fast as to equilibrate their frequencies immediately. The blood and lymph nodes were found to be compartmentalized rarely, while both the blood and lymph node were more frequently different from mucosal tissues. This study suggests that even oft-sampled blood does not fully capture the viral dynamics in other parts of the body, especially the gut where vRNA turnover was faster than the plasma and vDNA retained fewer wild-type viruses than other sampled compartments. Our findings of transient compartmentalization across multiple tissues may help explain the varied results of previous compartmentalization studies in HIV-1. HIV-1 is difficult to treat because the virus can evolve to become drug-resistant within the body, but we have an incomplete understanding of where drug-resistant viruses originate and how they spread within a person. In this study, four macaques were infected with RT-SHIV, a simian immunodeficiency virus with an HIV-1 reverse transcriptase coding region, which can be targeted with standard HIV drugs. We sampled virus from the macaques before, during and after their viral population became resistant to administered drugs and determined the genetic viral sequences in several parts of the body: blood, lymph nodes, gut, and vagina. We found that drug resistance emerged across compartments nearly simultaneously, and drug resistance evolved multiple independent times within each macaque. Although migration of RT-SHIV between compartments is fast, compartments do not have the same distribution of viral genotypes. This is important because although studies typically sample virus from the blood to study how HIV-1 evolution in humans, our study suggests that it is not fully representative of other parts of the body, particularly the gut.

15 August 2016 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
MCMackenzie L Cottrell
Mackenzie L Cottrell
HPHeather M. A. Pa-C Prince
Heather M. A. Pa-C Prince
AAAndrew Bs Allmon
Andrew Bs Allmon
KMKatie R. Mollan
Katie R. Mollan
MHMichael G. Hudgens
Michael G. Hudgens
AKAngela D. M. Kashuba
Angela D. M. Kashuba
Background: Quantifying tissue drug concentrations can yield important information during drug development, but complicates pharmacokinetic study design. Mucosal fluids collected by direct aspiration (cervicovaginal fluid; CVF) or swab (rectal fluid; RF) might be used as tissue concentration surrogates, but these relationships are not well characterized. Methods: Forty-nine healthy women, given a single oral dose of tenofovir, maraviroc, emtricitabine, or raltegravir at 50%–200% of the treatment dose, provided 13 plasma, 12 CVF, 12 RF and one cervical, vaginal and rectal tissue biopsy over 48 hours. Relationships between these paired samples were characterized by linear and multiple linear regression. Adjusted r2 values were used to select the final predictive models. Results: CVF exposure increased linearly with dose for all antiretrovirals (r2 ≥ 0.23, P ≤ 0.02) except raltegravir (r2 = 0.08, P = 0.19). In RF, only emtricitabine increased linearly with dose (r2 = 0.27, P = 0.01). For all antiretrovirals, CVF and RF concentrations significantly correlated with mucosal tissue concentrations (female genital tract r2 ≥ 0.37, rectal tissue r2 ≥ 0.50, P ≤ 0.001). In the final multivariate models, plasma and fluid concentrations were both associated with FGT concentrations for all antiretrovirals (r2 ≥ 0.81, P < 0.001). The same was noted for rectal tissue (r2 ≥ 0.58, P < 0.001) except for tenofovir, for which RF alone was predictive of tissue concentration (r2 = 0.91, P < 0.001). Conclusions: Mucosal fluids were positively correlated with tissue concentrations and including plasma concentrations improved the regression models in most cases. Dose linearity in CVF, but not RF, suggests a saturation process in lower gastrointestinal tract tissue. These findings suggest that mucosal fluid and plasma concentrations may be used for qualitative inference of tissue concentrations for these antiretrovirals.

31 January 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ADAaron S. Devanathan
Aaron S. Devanathan
JDJulie B. B Dumond
Julie B. B Dumond
DADaijha J.C. Anderson
Daijha J.C. Anderson
KMKristen Moody
Kristen Moody
APAmanda J. Poliseno
Amanda J. Poliseno
MCMackenzie L Cottrell
Mackenzie L Cottrell